Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study

Nicole Trepanowski¹, Michael S Chang², Guohai Zhou³, Maham Ahmad⁴, Elizabeth G Berry⁵, Katherine Bui⁶, William H Butler², Emily Y Chu⁷, Clara Curiel-Lewandrowski⁸, Laura E Dellalana⁹, Darrel L Ellis¹⁰, S Caleb Freeman⁵, Pavane L Gorrepati¹¹, Douglas Grossman¹², Samvel Gyurdzhyan¹³, Peter A Kanetsky¹⁴, Amber Loren Ong King⁴, Avani M Kolla¹⁵, Christine G Lian¹⁶, Jennifer Y Lin³, Vincent Liu¹⁷, Annie Lowenthal¹², Kelly N McCoy¹⁸, Ananya Munjal¹¹, Caitlyn N Myrdal¹⁹, Sara Perkins⁴, Jennifer G Powers²⁰, Corinne Rauck⁷, Tristan C Smart¹², Jennifer A Stein¹⁵, Suraj Venna²¹, Madalyn E Walsh²², Jennifer Y Wang²³, Sancy A Leachman²⁴, Susan M Swetter²⁵, Rebecca I Hartman²⁶

Affiliations

¹ Boston University School of Medicine, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
⁵ Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
⁶ Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
⁷ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
⁸ Division of Dermatology, The University of Arizona College of Medicine, Tucson, Arizona; The University of Arizona Cancer Center, Tucson, Arizona.
⁹ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
¹⁰ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Dermatology, Nashville VA Medical Centers, Nashville, Tennessee.
¹¹ University of Iowa Carver College of Medicine, Iowa City, Iowa.
¹² Department of Dermatology and Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.
¹³ Stanford University School of Medicine, Stanford, California.
¹⁴ Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
¹⁵ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
¹⁶ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
¹⁷ Departments of Dermatology and Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa.
¹⁸ University of Virginia, Charlottesville, Virginia.
¹⁹ Division of Dermatology, The University of Arizona College of Medicine, Tucson, Arizona.
²⁰ Department of Dermatology, University of Iowa Hospitals & Clinics, Iowa City, Iowa.
²¹ University of Virginia School of Medicine, Charlottesville, Virginia; Inova Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, Virginia.
²² Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa.
²³ Department of Dermatology/Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
²⁴ Department of Dermatology, Oregon Health & Science University, Portland, Oregon; Knight Cancer Institute at Oregon Health & Science University, Portland, Oregon.
²⁵ Department of Dermatology/Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Palo Alto, California; Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
²⁶ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, VA Integrated Service Network (VISN-1), Jamaica Plain, Massachusetts. Electronic address: rhartman@bwh.harvard.edu.

PMID: 35738513
PMCID: PMC9212700
DOI: 10.1016/j.jaad.2022.06.031

Multicenter Study

Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study

Nicole Trepanowski et al. J Am Acad Dermatol. 2022 Nov.

. 2022 Nov;87(5):1217-1219.

doi: 10.1016/j.jaad.2022.06.031. Epub 2022 Jun 20.

Authors

Affiliations

¹ Boston University School of Medicine, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
⁴ Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
⁵ Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
⁶ Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
⁷ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
⁸ Division of Dermatology, The University of Arizona College of Medicine, Tucson, Arizona; The University of Arizona Cancer Center, Tucson, Arizona.
⁹ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.
¹⁰ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Dermatology, Nashville VA Medical Centers, Nashville, Tennessee.
¹¹ University of Iowa Carver College of Medicine, Iowa City, Iowa.
¹² Department of Dermatology and Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.
¹³ Stanford University School of Medicine, Stanford, California.
¹⁴ Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
¹⁵ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
¹⁶ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
¹⁷ Departments of Dermatology and Pathology, University of Iowa Hospitals & Clinics, Iowa City, Iowa.
¹⁸ University of Virginia, Charlottesville, Virginia.
¹⁹ Division of Dermatology, The University of Arizona College of Medicine, Tucson, Arizona.
²⁰ Department of Dermatology, University of Iowa Hospitals & Clinics, Iowa City, Iowa.
²¹ University of Virginia School of Medicine, Charlottesville, Virginia; Inova Melanoma and Skin Cancer Center, Inova Schar Cancer Institute, Fairfax, Virginia.
²² Department of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa.
²³ Department of Dermatology/Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Palo Alto, California.
²⁴ Department of Dermatology, Oregon Health & Science University, Portland, Oregon; Knight Cancer Institute at Oregon Health & Science University, Portland, Oregon.
²⁵ Department of Dermatology/Pigmented Lesion and Melanoma Program, Stanford University Medical Center and Cancer Institute, Palo Alto, California; Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
²⁶ Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Department of Dermatology, VA Integrated Service Network (VISN-1), Jamaica Plain, Massachusetts. Electronic address: rhartman@bwh.harvard.edu.

PMID: 35738513
PMCID: PMC9212700
DOI: 10.1016/j.jaad.2022.06.031

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None disclosed.

Comment in

Letter from the Editor: Delays in melanoma diagnosis.
Elston DM. Elston DM. J Am Acad Dermatol. 2022 Sep;87(3):535. doi: 10.1016/j.jaad.2022.06.020. Epub 2022 Jun 16. J Am Acad Dermatol. 2022. PMID: 35718191 Free PMC article. No abstract available.

Cited by

Impact of the COVID-19 Pandemic on Melanoma Diagnosis in Romania-Data from Two University Centers.
Ungureanu L, Apostu AP, Vesa ȘC, Cășeriu AE, Frățilă S, Iancu G, Bejinariu N, Munteanu M, Șenilă SC, Vasilovici A. Ungureanu L, et al. Int J Environ Res Public Health. 2022 Nov 16;19(22):15129. doi: 10.3390/ijerph192215129. Int J Environ Res Public Health. 2022. PMID: 36429847 Free PMC article.
Early survival for patients newly diagnosed with cancer during COVID-19 in Ontario, Canada: A population-based cohort study.
Fu R, Sutradhar R, Li Q, Kamalraj P, Dare A, Hanna TP, Chan KKW, Irish JC, Coburn N, Hallet J, Singh S, Parmar A, Earle CC, Lapointe-Shaw L, Krzyzanowska MK, Louie AV, Mahar A, Urbach DR, McIsaac DI, Enepekides D, Gomez D, Look Hong NJ, Tinmouth J, Eskander A. Fu R, et al. Cancer Med. 2023 May;12(10):11849-11859. doi: 10.1002/cam4.5861. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999960 Free PMC article.
Indirect Impact of Pandemic on the Diagnosis of New Primary Melanoma: A Retrospective, Multicenter Study.
Nespoli L, Borgognoni L, Caliendo V, Piazzalunga D, Rossi P, Clementi M, Guadagni S, Caracò C, Sestini S, Valente MG, Picciotto F, Di Raimondo C, Ferrari D, Tucceri Cimini I, Giarrizzo A, Asero S, Mascherini M, De Cian F, Russano F, Fiore PD, Cavallin F, Coppola S, Pennacchioli E, Gallina P, Rastrelli M; SICO (Italian Society of Oncological Surgery) Study Group. Nespoli L, et al. J Clin Med. 2025 Mar 16;14(6):2017. doi: 10.3390/jcm14062017. J Clin Med. 2025. PMID: 40142827 Free PMC article.
Patients' Experiences and Communication with Teledermatology versus Face-to-Face Dermatology.
Leal-Costa C, Lopez-Villegas A, Perez-Heredia M, Baena-Lopez MA, Hernandez-Montoya CJ, Lopez-Liria R. Leal-Costa C, et al. J Clin Med. 2022 Sep 21;11(19):5528. doi: 10.3390/jcm11195528. J Clin Med. 2022. PMID: 36233398 Free PMC article.
The Epidemiology of Malignant Melanoma during the First Two Years of the COVID-19 Pandemic: A Systematic Review.
Toma AO, Prodan M, Reddyreddy AR, Seclaman E, Crainiceanu Z, Bloanca V, Bratosin F, Dumitru C, Pilut CN, Alambaram S, Vasamsetti NG, Decean L, Pricop M. Toma AO, et al. Int J Environ Res Public Health. 2022 Dec 25;20(1):305. doi: 10.3390/ijerph20010305. Int J Environ Res Public Health. 2022. PMID: 36612627 Free PMC article.

See all "Cited by" articles

References

1. Liu W., Dowling J.P., Murray W.K., et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142(12) doi: 10.1001/archderm.142.12.1551. - DOI - PubMed
1. Molinier R., Roger A., Genet B., et al. Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. J Eur Acad Dermatol Venereol. 2022;36(3):e164–e166. doi: 10.1111/jdv.17802. - DOI - PMC - PubMed
1. Davis C.H., Ho J., Greco S.H., et al. COVID-19 is affecting the presentation and treatment of melanoma patients in the Northeastern United States. Ann Surg Oncol. 2021;29(3):1629–1635. doi: 10.1245/s10434-021-11086-8. - DOI - PMC - PubMed
1. London J.W., Fazio-Eynullayeva E., Palchuk M.B., Sankey P., McNair C. Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clin Cancer Inform. 2020;4:657–665. doi: 10.1200/CCI.20.00068. - DOI - PMC - PubMed
1. Shellenberger R., Nabhan M., Kakaraparthi S. Melanoma screening: a plan for improving early detection. Ann Med. 2016;48(3):142–148. doi: 10.3109/07853890.2016.1145795. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study

Affiliations

Delays in melanoma presentation during the COVID-19 pandemic: A nationwide multi-institutional cohort study

Authors

Affiliations

Conflict of interest statement

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical